471 related articles for article (PubMed ID: 17046986)
1. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
Chue P
J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
[TBL] [Abstract][Full Text] [Related]
2. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
Turner MS; Stewart DW
J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
[TBL] [Abstract][Full Text] [Related]
3. Improving patient outcomes in schizophrenia: achieving remission.
Nasrallah HA; Lasser R
J Psychopharmacol; 2006 Nov; 20(6 Suppl):57-61. PubMed ID: 17046987
[TBL] [Abstract][Full Text] [Related]
4. Partial compliance in schizophrenia and the impact on patient outcomes.
Llorca PM
Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
6. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
Burton S
J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
[TBL] [Abstract][Full Text] [Related]
7. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
Faludi G
Neuropsychopharmacol Hung; 2005 Mar; 7(1):22-7. PubMed ID: 16167464
[TBL] [Abstract][Full Text] [Related]
8. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
9. A survey of patient satisfaction with and subjective experiences of treatment with antipsychotic medication.
Gray R; Rofail D; Allen J; Newey T
J Adv Nurs; 2005 Oct; 52(1):31-7. PubMed ID: 16149978
[TBL] [Abstract][Full Text] [Related]
10. Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics.
Watanabe A; Shibata I; Kato T
Psychiatry Clin Neurosci; 2004 Jun; 58(3):268-73. PubMed ID: 15149292
[TBL] [Abstract][Full Text] [Related]
11. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
Yen CF; Cheng CP; Huang CF; Yen JY; Ko CH; Chen CS
Bipolar Disord; 2008 Jul; 10(5):617-24. PubMed ID: 18657246
[TBL] [Abstract][Full Text] [Related]
12. Strategies for dosing and switching antipsychotics for optimal clinical management.
Buckley PF; Correll CU
J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
[TBL] [Abstract][Full Text] [Related]
13. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
Naber D; Lambert M; Karow A
Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
[TBL] [Abstract][Full Text] [Related]
14. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
Kasper S
Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
[TBL] [Abstract][Full Text] [Related]
15. Compliance and the rehabilitation alliance.
Aquila R; Weiden PJ; Emanuel M
J Clin Psychiatry; 1999; 60 Suppl 19():23-7; discussion 28-9. PubMed ID: 10507277
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic alliance, a stake in schizophrenia].
Charpentier A; Goudemand M; Thomas P
Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
[TBL] [Abstract][Full Text] [Related]
17. Sexual dysfunction in schizophrenia: focus on recent evidence.
Baggaley M
Hum Psychopharmacol; 2008 Apr; 23(3):201-9. PubMed ID: 18338766
[TBL] [Abstract][Full Text] [Related]
18. The long term--maximising potential for rehabilitation in patients with schizophrenia.
Fagiolini A; Goracci A
Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S123-9. PubMed ID: 17336767
[TBL] [Abstract][Full Text] [Related]
19. The case for long-acting antipsychotic agents in the post-CATIE era.
Nasrallah HA
Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
[TBL] [Abstract][Full Text] [Related]
20. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
